Physician profile
Caroline Stagg
NPI 1548751415
$3,354.69
in general payments reported to CMS, 2019-2025
29 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,796 · 2022: $437 · 2023: $468 · 2024: $444 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $609.61 | 2021-2022 | |
| Abbvie INC. | $571.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $415.58 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $300.02 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $247.93 | 2021-2022 | |
| Advanced Respiratory, INC | $168.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $131.59 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.26 | 2021-2024 | Jardiance |
| Abbott Laboratories | $83.52 | 2021-2024 | Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $66.86 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.00 | 2021 | |
| Genzyme Corporation | $61.54 | 2021 | |
| Mayne Pharma Commercial LLC | $61.36 | 2021 | |
| Novo Nordisk INC | $53.83 | 2022-2023 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $52.68 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $44.38 | 2022 | |
| Amgen INC. | $44.11 | 2022-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $42.97 | 2021 | |
| Electromed, INC. | $36.23 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.31 | 2021 | |
| Esperion Therapeutics, INC. | $24.85 | 2022 | |
| Ethicon INC. | $23.53 | 2022 | |
| Dexcom, INC. | $16.64 | 2023 | Dexcom G6 Transmitter |
| Phadia US INC. | $16.50 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.07 | 2025 | Xifaxan |
| Grifols USA, LLC | $15.02 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.73 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.51 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Stagg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.